Reconstitution of DC1 and DC2 subpopulations after allogeneic SCT. (A) FACS analysis of DC1 and DC2 in PB and BM samples from a healthy donor and a patient 30 days after SCT (for details, see “Patients, materials, and methods”). Lin^–HLA-DR⁺ cells (gate R1) were further analyzed for the presence of CD11c⁺CD123^low DC1 subset (gate R2) and CD11c^–CD123^high DC2 subset (gate R3). DC1 and DC2 content is expressed as a percent of total nucleated cells. (B) DC1 (•) and DC2 (○) in PB and BM of individual healthy donors (N) and patients after SCT. Time after transplantation and mean values are indicated. *P < .05, **P < .005 compared with healthy controls.